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The application of percutaneous tra~s~urn~~a~ coronary an- 
gioplasty to patients with a high ris clinical profile is 
widespread in experienced intervent nal centers (L-4). 
Higher procedure-related morbidity and mortality have been 
shown for patients with poor left ventricular function, left 
main coronary or left main equivalent occlusive disease, age 
>70 years, combined iagnostic catheterization a d coro- 
nary angioplasty for unstable angina nd dilation of all three 
major coronary arteries (4). The hemodynamic conse- 
quences of reduced coronary flow during balloon inflation or 
acute coronary occlusion are greater in these subsets of 
patients and have prompted consideration of means of 
supporting the circulation during coronary angi 
cedures (5). The use of combined coronary ang 
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intraaortic balloon pump counterpu~sati~n was 
angioplasty exu?rience (6) in high risk 
few reports have followed demonst 
usefulness ofthis strategy (7-9). 
Recently, the prophylactic use of percutaneous cardio- 
pulmonary bypass has been suggested as an alternative 
method for “supported” high risk coronary angioplasty 
(10-16). In our current practice of coronary angio 
have used prophylactic ntraaortic balloon pump support 
when hemodynamic support was believed to be desirable for 
the performance of high risk coronary angioplasty (3,417). 
In this report we describe our results with this approach. 
ts. Between January 1, 1987 and June 3 
19g9, we deformed 3,408 coronary angioplasty procedures. 
Three hundred thirty-six procedures were c 
the setting of acute myocardial infarction and 3,072 were 
elective or urgent coronary angioplasty procedures for stable 
or unstable ischemic syndromes. Detailed patient profiles 
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Table 1. Use of Intraaortic Balloon Counterpulsation in 3,408 
Angioplasty Procedures 
No. of Patients No. of Patients 
Acute myocardial infarction 31 
Acute coronary OcChISiOn 9 
Miscellaneous 6 
Air embolism 2 
Cardiac arrest 2 
Anaphylaxis I 
Procedural hypotension 1 
ProphylaLtic support 28 
Male/female ratio 
Age (yr) 
Age a70 years 
Prior bypass surgery 
Class 111 or IV angina pectoris 
Three vessel coronary artery disease 
Two vessel coronary artery disease 
Left main coronary artery disease 
Left ventricular ejection fraction 
Ejection fraction ~30% 
2513 
66 -C 8 (range 51 to 81) 
10 (36%) 
9 (32%) 
23 (82%) 
26 (93%) 
2 (7%) 
7 (‘5%) 
24 k 8% (range 15% to 50%) 
25 (89%) 
and procedural nd clinical outcomes from a!! interVeRtiORS 
were entered prospectively into a computerized coronary 
angioplasty data base. During this time, an intraaortic bal- 
loon pump was used in combination with coronary angio- 
plasty in 74 patients (Table I). In 31 patients, intraaortic 
balloon pump support was used in the setting of coronary 
angioplasty during acute myocardial infarction with shock or 
extensive myocardial damage (9% of infarct procedures!. In 
nine patients emergency placement of an intraaortic balloon 
pump was required for the management of acute coronary 
occlusion occurring during coronary angioplasty . An in- 
traaortic balloon pump was used in an additional six pa- 
tients, for anaphylaxis in one, major coronary air embolism 
in two, cardiac arrest in two and recurrent hypotension 
during coronary angioplasty in one. 
In the remaining 28 patients (0.9% of elective or urgent 
coronary angioplasty procedures) an inrraaortic balloon 
pump was placed at the beginning of an elective coronary 
angioplasty procedure ina prophylactic manner for patients 
with perceived high risk features. The decision to use an 
intraaortic balloon pump for supported coronary angioplasty 
was made at the discretion of the staff interventionalist and 
was not determined byprotocol. This report focuses on this 
group of 28 patients. 
Angioplasty protocol. On the patient’s arrival at the car- 
diac catheterization suite, both femoral regions were pre- 
pared and draped. A 10.5 F intraaortic balloon pump (Data- 
scope) was placed percutaneously from the left femoral 
artery and balloon counterpulsation was initiated. After 
placement of the right femoral sheath, the patient received 
10,000 U heparin. Unless contraindicated, routine premedi- 
cations consisted of 325 mg aspirin orally, 5 mg isosorbide 
dinitrate sublingually, 75 mg lidocaine intravenously and 5 
mg verapamil intravenously. Anadditional 5,000 U heparin 
was given every hour of the angioplasty procedure. 
Coronary angioplasty was performed with a variety of 
over-the-wire andfixed-wire balloon catheters. During most 
of the study, autoperfusion balloon catheters were not 
available and were not used (18). Typically, three to five 
inflations lasting 45 to 120 swere performed across the lesion 
using pressure sufficient to achieve full balloon expansion. 
Table 2. Clinical Characteristics of 28 Patients With Supported 
High Risk Coronary Angioplasty 
Shorter balloon inflations were used if severe angina pectoris 
or important hypotension ccurred. Exquisite attention was 
given to the guide catheter position, with immediate with- 
drawal of the guide catheter f om the target vessel after 
balloon catheter delivery into the artery or vein graft. Aortic 
pressure was measured continuously from the guide cathe- 
ter. The angioplasty procedure was considered successful if 
the residual stenosis was ~40% in al! views and if there were 
no major procedural complications (resulting indeath, myo- 
cardial infarction or need for emergency oronary bypass 
surgery). Patients were maintained on 325 mg aspirin three 
times daily, 75 mg dipyridamole three times daily and an oral 
calcium channel blocker. 
Statistics. Data are re orted as mean values + I SD. 
clinical characterisUics (Tables 2and 3). There were 25 
men and 3 women with a mean age of 66 t 8 years (range 51 
to 81); IO patients were ~70 years old. Previous coronary 
bypass urgery had been performed innine patients, one of 
whom had two prior operations. Twenty-three patients had 
New York Heart Association functional class II1 or 1V 
angina pectoris, and the others had abnormal responses to
exercise treadmill testing. Associated diseases included ia- 
betes mellitus in two, severe chronic obstructive pulmonary 
disease in four and morbid obesity in one patient. 
The angiographic results in this group are /isred in Table 
‘Table 3.High Risk Designations in 28 Patients With Supported 
Coronary Angioplasty 
-_ 
No. of Patients 
Severe ventricular dysfunction 
Single remaining circulation and severe ventricular 
dysfunction 
16 
3 
Single remaining circulation 1 
Left main disease and severe ventricular dysfunction 5 
Left main disease 2 
Three vessel dilation and severe ventricular dysfunction I 
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No. of Patients 
ultlvessel angiopiasty 
Vessels with attempted dilation 
?I 
Left main coronary artery 5 
Left anterior descending artery I5 
Right coronary artery 14 
Left circumflex arIery 13 
Saphenous vein graft 8 
Lesions successfully dilated 90194 (967f ) 
Procedural hypotension 11 
Procedural death 0 
Complications of balloon pump 3 (II%) 
hree vessel ~6x011 
main coronary artery. 
remained patent and supplied all the coronary circulation. 
Seven patients had stenosis of the left main corc9nary artery: 
five of these seven patients also had severe left ventricular 
dysfunction. In all patients cardiac surgical c
our institution or at the referring ~~stituti~~ 
either an extreme risk fo 
onary angioplasty was performed in 21 of the 28 patients. 
Ninety i36%) of 94 lesions were successfully dilated. 
creases in systemic systolic blood pressure to <Xl mm 
were noted during 11 procedures, but augmented diastolic 
pressure remained >90 m Hg at all times and the coronary 
angioplasty was complet in all patients. Inno patient was 
the procedure compromised orcurtailed because of hemo- 
dynamic instability. No patient lost consciousness and an 
intravenous pressor (dopamine) was required transiently in
only one patient. There were no deaths or myocardial 
infarctions as detected by serial electrocardiography and
cardiac enzyme determinations within ‘72 h of the coronary 
angioplasty. No patient was urgently referred for cardiac 
surgery. in four patients increases insystolic blood pressure 
after revascula,+ation permitted removal of the intraaortic 
t~a~~oo~ pump at the end of the procedure and in the 
I’emainder it was removed the following morning. 
Complications. Peripheral vascular complications from 
the intraaortic balloon pump occurred in three patients. Two 
patients developed coolness of the limb ipsilateral to the 
intraaortic balloon 
pulsation i  a~tic~pati~~ of atory instability appears to 
dural adverse vents. Vas- 
compares favorably with those of larger studies ofintraaortic 
placement (19,20). 
es. The elective use of intraaortic balloon 
pump support for the prevention of procedural complica- 
tions has received little attention (6-9). 0ur results are 
similar to those of Szatmary and Marco (9) for 13 patients 
with unstable angina in whom an intraaortic balloon pump 
was used preventively for poor left ventricular function, 
refractory chest pain or hypotension. Angiographic and 
clinical improvement was noted in 12 (96%) of their 13 
patients without myocardial infarction or death. My 2 of 
the 13 patients had a left ventricular ejection fraction S30%, 
in st with 
atory s 
methods to support he c 
plasty in patients at risk 
light of the recent attention given to the elective use Of 
percutaneous cardiopu!mondry bypass ~ur~ag hi h risk COT- 
onary angioplasty (IO-IS). The procedure involves the Per- 
cutaneous femoral introduction of 18F to 20F catheters intO 
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the right atrium and distal aorta connected toa blood Pump, 
oxygenator and heat exchanger (11). Circulatory flows of 3 
to 5 literdmin are attainable in most patients. This equip- 
ment is available as a self-contained, portable unit and is 
marketed for high risk coronary angioplasty. Fublished 
results in approximately 50 patients (10-M suggest low 
procedural mortality and hi&procedural success rates com- 
parable to those reported inour series of patients. Vascular 
complications are anticipated to be more frequent with 
percutaneous cardiopulmonary bypass than with intraaortic 
balloon pump support because of the larger size of the 
catheters involved. In a reported series (16) of 43 patients 
undergoing percutaneous cardiopulmonary b pass during 
emergency oronary angioplasty (8 patients) or elective high 
risk coronary angioplasty (35 patients), femoral comphca- 
tions occurred 11 times (femoral rtery repair in 2, pseudo- 
aneurysm in2, infection at the entry site in 4, femoral nerve 
weakness in 2 and venous thrombosis n 1). In addition, 
several liters of blood that cannot be returned to the patient 
usually remain in the system, necessitating blood transfusion 
therapy and its risks in the majority of patients (10,11,16). 
Although not yet reported for percutaneous cardiopulmo- 
nary bypass used during coronary angioplasty, cardiopulmo- 
nary bypass used during cardiac surgery is associated with 
several unique adverse clinical syndromes including tran- 
sient intellectual dysfunction (21,22). 
Finally, concern for the greater use of percutaneous 
cardiopulmonary b pass during elective supported angio- 
plasty arises from the limitations of the support provided. 
Although flows of 3 to 5 literslmin may be adequate to 
provide continued perfusion to the brain and kidneys during 
a procedural complication such as acute coronary occlusion, 
in the absence of anterograde coronary flow myocardial 
necrosis would result. In patients with severe left ventricular 
dysfunction, left main coronary artery disease or only a 
single remaining coronary vessel to the heart, a scenario f 
continuing cerebral and renal function in the presence of 
inadequate cardiac function to support life is possible and 
frightening. This would expose the interventionalist to anew 
spectrum ofmedical and ethical issues, such as terminating 
life support in conscious patients without adequate cardiac 
function unless upported by cardiopulmonary bypass. The 
coronary angioplasty results we observed with high risk 
patients using contemporary guiding catheters, guide wires 
and balloon catheters in conjunction with prophylactic in- 
traaortic babn pump counterpulsation f rce the question 
of whether cardiopulmonary bypass upport is ever reason- 
able. Only a randomized trial of supported high risk core- 
nary angioplasty with intraaortic balloon pumping and car- 
diopulmonary b pass ystems will answer this question. 
Guidelines for patient selection. The selection ofpatients 
appropriate forelective coronary angioplasty supported with 
intraaortic balloon pump counterpulsation s based on con- 
siderations of coronary anatomy, left ventricuhtr function, 
amount of myocardium at risk and the patient’s overall 
clinical status. We currently believe that patients wit 
ventricular dysfunction (ejection fraction 130%) undergoing 
coronary angioplasty of vessels upplying remaining viable 
myocardium are candidates for intraaortic balloon pump 
support. It is also our recommendation that most patients 
undergoing coronary angioplasty of a left main coronary 
stenosis not protected by a patent bypass graft to the left 
coronary system have intraaortic balloon pump support for 
safe hemodyna 
only one conduit remaining 
undergo dilation of that co 
prophylactic intraaortic balloon pump 
multivessel coronary angioplasty compl 
hypotension, intraaortic balloon pump placement early in 
the procedure is reasonable to avoid occlusion of previously 
dilated sites (4). Given these guidelines, it is noteworthy that 
we utilized prophylactic intraaortic balloon pump support in 
only 0.9% of elective or urgent coronary angioplasty proce- 
dures during the study period, attesting to the ability to 
perform coronary angioplasty safely and effectively in the 
majority of patients without support. For example, for all 
patients treated acutely or electively with coronary angio- 
plasty during 1987 and 1988, we performed ilation in 465 
patients with an ejection fraction <40%, 57 with left main 
coronary occlusive disease and 642 patients over the age of 
70 years, and used an int balloon pump prophylacti- 
cally or therapeutically in o patients. Evidence that we 
did not underuse intraaortic balloon pump support during the 
30 month study period is provided by the need to insert an 
intraaortic balloon pump during coronary angioplasty for 
refractory hypotension rcardiac arrest unrelated to acute 
occlusion i  only three patients. 
tations. There are several limitations of the 
current study. Although the data were collected and entered 
prospectively into a computerized data base of our overall 
coronary angioplasty experience, the patients described 
were identified retrospectively. The decision to place an 
intraaortic balloon pump prophylactically was not in the 
protocol, although the indications used by the intervention- 
alists performing coronary angioplasty at our institution 
were similar. The patients were not randomized according to
use of an intraaortic balloon pump or no use of a pump, so it 
cannot be stated with certainty hat intraaortic balloon pump 
support promoted safety and success of the coronary angio- 
plasty procedure. The high success rate and low complica- 
tion rate in this group of patients, generally atincreased risk 
for procedural complications, suggest that the intraaortic 
balloon pump played a supportive role. Finally, during the 
period of this study, coronary autope 
ters were not generally available (18). These devices may 
offer an alternative or supplementary pproach in selected 
patients with a large mass of myocardium at risk (18). 
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